drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Allogeneic CD45RA− memory T cells engineered with an anti-CD19 chimeric antigen receptor containing 4-1BB/CD3ζ signaling domains to target and kill CD19+ B-lineage leukemia cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Immunotherapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic CD45RA− memory T cells engineered to express an anti‑CD19 chimeric antigen receptor with 4‑1BB costimulation and CD3ζ signaling recognize CD19 on B‑lineage leukemia cells, triggering T‑cell activation and cytotoxic killing; 4‑1BB enhances proliferation and persistence, and use of memory (CD45RA−) T cells aims to improve durability and reduce GVHD risk.
drug_name
CD19-CAR(Mem) T cells
nct_id_drug_ref
NCT04881240